Acurx Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Acurx Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Acurx Pharmaceuticals, Inc.’s insiders pay?

From November 22, 2021 to January 8, 2025, 6 insiders reported 12 open-market purchases and 0 sales not made under a pre-set plan in Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Deluccia Robert J	Director	3	—	—	—	January 8, 2025
Luci David P	President and CEO	3	—	—	—	January 8, 2025
Sailer Carl	Director	3	—	—	—	January 8, 2025
Dean Jack H	Director	1	—	—	—	January 8, 2025
Donohue James J.	Director	1	—	—	—	January 8, 2025
Scodari Joseph C	Director	1	—	—	—	January 8, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Acurx Pharmaceuticals, Inc. · Funds · Politicians